TABLE 5.

ANALYSES OF PRIOR AND PROSPECTIVE 2-YEAR COPD EXACERBATIONS IN THE SUBJECTS WITH COPD FROM THE ECLIPSE COHORT^*

Effect	Incidence Rate Ratio	95% Confidence Interval	P Value
Prior Exacerbations
rs13118928 (HHIP)	0.877	0.78–0.975	0.015
rs8034191 (CHRNA)	0.971	0.869–1.084	0.598
rs7671167 (FAM13A)	1.081	0.978–1.195	0.129
Female	1.173	1.004–1.372	0.044
Pack-years smoked	1	0.997–1.002	0.763
Age	1.002	0.992–1.011	0.754
Prospective Exacerbations (2-yr data)
rs13118928 (HHIP)	0.906	0.832–0.987	0.024
rs8034191 (CHRNA)	1.017	0.930–1.113	0.709
rs7671167 (FAM13A)	1.028	0.943–1.22	0.528
Female	1.202	1.061–1.36	0.004
Pack-years smoked	1	0.997–1.002	0.726
Age	1.01	1.001–1.018	0.021

Definition of abbreviations: COPD = chronic obstructive pulmonary disease; ECLIPSE = Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points.

^*All 1,719 subjects from the ECLIPSE cohort were used in this analysis. The associations of the HHIP, FAM13A, and CHRNA single-nucleotide polymorphisms with prior exacerbations (exacerbations during the 12 mo before study entry that required antibiotics, systemic corticosteroids, or hospitalization) and prospective exacerbations (exacerbations over the first 2 yr of the study that required antibiotics, systemic corticosteroids, or hospitalization) were assessed by negative binomial regression models. Robust SE for the model coefficients were determined by generalized estimating equations. An offset variable based on the log of the number of days on study was included in the model for prospective exacerbations.